Posttreatment Complications in Pediatric Cervical Neuroblastoma: A Retrospective Case Series at a Tertiary Cancer Center

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2023 Oct 18

PMID 37850570

Authors

Joseph Lopez

Tejas Subramanian

Jonathan Durell

Helena Levyn

Richard Wong

Jatin Shah

Michael P LaQuaglia

Justin Ted Gerstle

Affiliations

Soon will be listed here.

Abstract

Background: Neuroblastomas rarely occur as primary tumors in the cervical region. Therefore, very little has been reported regarding treatment strategies, complications, and outcomes of these cervical neuroblastomas. The goal of this study is to review the presentation, management, and outcomes of all primary cervical pediatric neuroblastoma cases at a single tertiary care center.

Methods: A retrospective cohort review of all neuroblastoma patients treated at a single center were performed. All patients with primary cervical neuroblastoma were reviewed for demographic information, tumor characteristics, treatment, and outcomes.

Results: Thirty (1.8%) patients were found to have undergone treatment for cervical neuroblastoma tumors diagnosed on average at 2.1 years old. Most presented with a swollen neck/palpable mass ± Horner's syndrome. Based on features including tumor staging, N-myc proto-oncogene protein (MYCN) amplification status, histology, most were deemed intermediate or high risk. Treatment strategies centered around chemotherapeutic regimens with surgery when possible as well as various adjuvant treatments including radiation therapy, immunotherapy, bone marrow transplant, and a neuroblastoma vaccine. Ten (33.3%) of patients experienced treatment-related complications and four (13.3%) died as a result of their disease progression. All four patients were high-risk patients, two of which had MYCN amplification.

Conclusion: Cervical neuroblastomas generally have favorable outcomes. These tumors can be treated effectively with chemotherapy and surgical intervention with various adjuvant therapies. MYCN amplification and higher stage disease presentation contribute to worse outcomes.

References

Schwab M . Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin Cancer Biol. 1993; 4(1):13-8. View

Csanady M, Vass G, Bartyik K, Majoros V, Rovo L . Multidisciplinary management of cervical neuroblastoma in infants. Int J Pediatr Otorhinolaryngol. 2014; 78(12):2103-6. DOI: 10.1016/j.ijporl.2014.09.015. View

Sokol E, Desai A . The Evolution of Risk Classification for Neuroblastoma. Children (Basel). 2019; 6(2). PMC: 6406722. DOI: 10.3390/children6020027. View

Vo K, Matthay K, Neuhaus J, London W, Hero B, Ambros P . Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014; 32(28):3169-76. PMC: 4171360. DOI: 10.1200/JCO.2014.56.1621. View

Miodosky M, Abdul-Hai A, Tsirigotis P, Or R, Bitan M, Resnick I . Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate. Bone Marrow Transplant. 2006; 38(7):507-11. DOI: 10.1038/sj.bmt.1705474. View

Park J, Eggert A, Caron H . Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008; 55(1):97-120, x. DOI: 10.1016/j.pcl.2007.10.014. View

Bordow S, Norris M, Haber P, Marshall G, Haber M . Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol. 1998; 16(10):3286-94. DOI: 10.1200/JCO.1998.16.10.3286. View

Abramson S, Berdon W, Ruzal-Shapiro C, Stolar C, Garvin J . Cervical neuroblastoma in eleven infants--a tumor with favorable prognosis. Clinical and radiologic (US, CT, MRI) findings. Pediatr Radiol. 1993; 23(4):253-7. DOI: 10.1007/BF02010908. View

Brown R, Szymula N, LORE Jr J . Neuroblastoma of the head and neck. Arch Otolaryngol. 1978; 104(7):395-8. DOI: 10.1001/archotol.1978.00790070033009. View

10.

Castellote A, Vazquez E, Vera J, Piqueras J, Lucaya J, Garcia-Pena P . Cervicothoracic lesions in infants and children. Radiographics. 1999; 19(3):583-600. DOI: 10.1148/radiographics.19.3.g99ma08583. View

11.

Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T . Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignancies. Bone Marrow Transplant. 1998; 21(3):281-6. DOI: 10.1038/sj.bmt.1701082. View

12.

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

13.

Qureshi S, Kembhavi S, Ramadwar M, Chinnaswamy G, Laskar S, Talole S . Outcome and morbidity of surgical resection of primary cervical and cervicothoracic neuroblastoma in children: a comparative analysis. Pediatr Surg Int. 2013; 30(3):267-73. DOI: 10.1007/s00383-013-3431-4. View

14.

Haddad M, Triglia J, Helardot P, Couanet D, Gauthier F, Neuenschwander S . Localized cervical neuroblastoma: prevention of surgical complications. Int J Pediatr Otorhinolaryngol. 2003; 67(12):1361-7. DOI: 10.1016/j.ijporl.2003.08.046. View

15.

Zafeiriou D, Economou M, Koliouskas D, Triantafyllou P, Kardaras P, Gombakis N . Congenital Horner's syndrome associated with cervical neuroblastoma. Eur J Paediatr Neurol. 2006; 10(2):90-2. DOI: 10.1016/j.ejpn.2006.01.004. View

16.

Chan H, Gallie B, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J . MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res. 1998; 3(10):1699-706. View

17.

van der Lelie H, Baars J, Rodenhuis S, van Dijk M, Thomas B, Van Oers R . Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer. 1995; 76(11):2338-42. DOI: 10.1002/1097-0142(19951201)76:11<2338::aid-cncr2820761123>3.0.co;2-p. View

18.

Smith M, Smith R, Bailey C . Primary cervical neuroblastoma in infants. J Laryngol Otol. 1985; 99(2):209-14. DOI: 10.1017/s0022215100096560. View

19.

Jackson J, Tran H, Stein J, Shimada H, Patel A, Marachelian A . The clinical management and outcomes of cervical neuroblastic tumors. J Surg Res. 2016; 204(1):109-13. PMC: 9341276. DOI: 10.1016/j.jss.2016.04.030. View